期刊文献+

驱动蛋白Kif2a在乳腺癌组织芯片中的表达及临床意义 被引量:3

Expression and clinical significance of Kif2a in breast carcinoma by the application of tissue microarray
下载PDF
导出
摘要 目的:研究乳腺癌组织芯片中驱动蛋白Kif2a的表达及临床意义。方法:采用组织芯片技术及免疫组织化学方法检测102例乳腺癌及癌旁组织中Kif2a的表达。对有随访结果的62例作单因素、多因素相关生存分析。结果:乳腺癌组织与癌旁组织中Kif2a的表达比较差异有统计学意义。Kif2a在乳腺癌中的表达与淋巴结转移、HER2表达呈正相关(P<0.05)。在随访的62例中,单因素分析显示:乳腺癌中Kif2a表达、淋巴结转移、HER2表达均与患者生存率有关,多因素Cox比例风险分析显示均具有独立的预后意义。结论:Kif2a在乳腺癌组织中的表达与淋巴结转移、HER2表达呈正相关(P<0.05)。Kif2a表达水平的检测对乳腺癌的预后判断具有重要意义。 Objective To study the expression and clinical significance of Kif2 a in breast carcinoma by the application of tissue microarray. Methods Tissue microarray and immunohistochemistry method(S-P) were used to examine the expression of Kif2 a in 102 cases of breast carcinoma tissue and adjacent tissue. The prognosis of 62 cases followed up were studied by both univariate and multivariate analysis. Results The expression of Kif2 a has significant difference between breast carcinoma tissue and adjacent tissue. Kif2 a expression were associated with lymph nodal involvement and HER2 expression(P 0.05). In the 62 cases with followed-up data, univariante analysis revealed that the expression of Kif2 a, lymph nodal involvement and HER2 expression were correlated with the survival rate. Cox stepwise proportional hazards analysis showed that they were independently prognostic factors.Conclusions Kif2 a expression in breast carcinoma were associated with lymph nodal involvement and HER2expression(P 0.05). It is meaningful to examine Kif2 a expression for prognosis of the breast carcinoma.
出处 《实用医学杂志》 CAS 北大核心 2016年第16期2663-2666,共4页 The Journal of Practical Medicine
基金 江苏省南通市卫生局青年科研基金项目(编号:WQ2014022)
关键词 Kif2a 组织芯片 乳腺癌 免疫组织化学 Kif2a Tissue microarray Breast carcinoma Immunohistochemistry
  • 相关文献

参考文献4

二级参考文献36

  • 1吴名耀,郑瑞明,李乔山.乳腺癌癌基因产物和激素受体的免疫组化研究[J].临床与实验病理学杂志,1996,12(2):183-184. 被引量:10
  • 2张瑰红,施达仁,梁晓曼,侯景辉,康苏娅,朱卫东,李晓兵,邵云,陈丽荣,周燕.显色原位杂交和免疫组织化学检测乳腺癌HER2/neu基因状况和蛋白表达的对照性研究[J].中华病理学杂志,2006,35(10):580-583. 被引量:29
  • 3<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:163
  • 4阮伶.c-erbB-2 癌基因产物在乳腺良、恶性病变中的表达[J].广西医学,1997,19(2):157-159. 被引量:3
  • 5Carey L A,Perou C M.Race breast cancer subtypes andsurvival in the Carolina Breast Cancer Study[J].JAMA,2006,295(21):2492-2502.
  • 6Nie L O,Hsu F D,Jensen K,et al.Immunoh is to chemicaland clinical characterization of the basal-like-subtype ofinvasive breast carcinoma[J].Clin Cancer Res,2004,10(16):5367.
  • 7Vogel C L,Cobleigh M A,Tripathy D,et al.First-lineherceptinmonotherapy in metastatic breast cancer[J].Oncology,2001,61(Suppl):37-42.
  • 8Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer [ J]. J Clin Oncol, 2007, 25 (33) :5287-5312.
  • 9Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Chnical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[ Jl. J Clin Oncol, 2007, 25 ( 1 ) : 118- 145.
  • 10Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth faetor reeeptor 2 testing in breast eaneer: American Society of Clinical Oneology/College of American Pathologists clinical practice guideline update[J]. J Clin Oneol, 2013, 31 (31) :3997-4013.

共引文献415

同被引文献33

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部